Sulindac, a non-steroidal anti-inflammatory drug, mediates breast cancer inhibition as an immune modulator

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Yin, Tao ^a   Wang, Guoping ^a   Ye, Tinghong ^a   Wang, Yongsheng ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AUTACOID; CYTOKINE; IMMUNOLOGIC FACTOR; NONSTEROID ANTIINFLAMMATORY AGENT; SULINDAC;

ADAPTIVE IMMUNITY; ANIMAL; BREAST NEOPLASMS; DISEASE MODEL; DRUG EFFECTS; HUMAN; IMMUNOLOGY; IMMUNOMODULATION; LYMPHOCYTE DEPLETION; MACROPHAGE; METABOLISM; METASTASIS; MORTALITY; MOUSE; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL LINE; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

ADAPTIVE IMMUNITY; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BREAST NEOPLASMS; CELL LINE, TUMOR; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; INFLAMMATION MEDIATORS; LYMPHOCYTE DEPLETION; MACROPHAGES; MICE; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; SULINDAC; T-LYMPHOCYTE SUBSETS; TUMOR BURDEN; TUMOR MICROENVIRONMENT;

EID: 84955164931     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep19534     Document Type: Article

References (47)

1. Agarwal, S., Reddy, G. V., & Reddanna, P. Eicosanoids in inflammation and cancer: the role of COX-2. Expert Rev. Clin. Immunol. 5, 145-165 (2009
2. Tondera, C., et al. Optical imaging of COX-2: studies on an autofluorescent 2, 3-diaryl-substituted indole-based cyclooxygenase-2 inhibitor. Biochem. Biophys. Res. Commun. 458(1), 40-45 (2015
3. Pasche, B. Aspirin-from prevention to targeted therapy. N. Engl. J. Med. 367, 17 (2012
4. Fulton, A. M. In vivo effects of indomethacin on the growth of murine mammary tumors. Cancer Res. 44, 2416-2420 (1984
5. Strong, H. A., Warner, N. J., Renwick, A. G., & George, C. F. Sulindac metabolism: the importance of an intact colon. Clin. Pharmacol. Ther. 38, 387-393 (1985
6. Duggan, D. E., Hooke, K. F., Risley, E. A., Shen, T. Y., & van Arman, C. G. Identification of the biologically active form of sulindac. J. Pharm. Exp. Ther. 201, 8-13 (1977
7. Duggan, D. E., Hooke, K. F., & Hwang, S. S. Kinetics of the tissue distributions of sulindac and metabolites. Relevance to sites and rates of bioactivation. Drug Metab. Dispos. 8, 241-246 (1980
8. Giardiello, F. M., et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med 328, 1313-1316 (1993
9. Fulton, A., Roi, L., Howard, L., Russo, J., Brooks, S., & Brennan, M. J. Tumor-Associated prostaglandins in patients with primary breast cancer: relationship to clinical parameters. Breast Cancer Res. Treat. 2, 331-337 (1982
10. Harris, R. E., Namboodiri, K. K., & Farrar, W. B. Nonsteroidal anti-inflammatory drugs and breast cancer. Epidemiology 7, 203-205 (1996
11. Bennett, A., Berstock, D. A., Raja, B., & Stamford, I. F. Survival time after surgery is inversely related to the amounts of prostaglandins extracted from human breast cancers. Br. J. Pharmacol. 66, 451 (1979
12. Rolland, P. H., Martin, P. M., Jacquemier, J., Rolland, A. M., & Toga, M. Prostaglandin in human breast: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastia cells. J. Nati. Cancer Inst. 64, 1061-1070 (1980
13. Fulton, A. M., & the Breast Cancer Prognostic Study Clinical Associates. Prostaglandin levels in mammary tumors of varying malignant potential. Proc.Am. Assoc. Cancer Res. 22, 61 (1981
14. Kollmorgen, G. M., King, M. M., Kosanke, S. D., & Do, C. Influence of dietary fat and indomethacin on the growth of transplantable mammary tumors in rats. Cancer Res. 43, 4714-4719 (1983
15. Thompson, H. J., et al. Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res. 57, 267-271 (1997
16. Loveridge, C. J., MacDonald, A. D., Thoms, H. C., Dunlop, M. G., & Stark, L. A. The proapoptotic effects of sulindac, sulindac sulfone and indomethacin are mediated by nucleolar translocation of the RelA(p65) subunit of NF-kB. Oncogene 27, 2648-2655 (2008
17. Hanif, R., et al. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem. Pharmacol. 52, 237-245 (1996
18. Piazza, G. A., et al. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res. 55, 3110-3116 (1995
19. Reimers, M. S., et al. Expression of HLA class I antigen, aspirin use, and survival after a diagnosis of colon cancer. J.A.M.A. Intern. Med. 174, 732-739 (2014
20. Chan, A. T., Ogino, S., & Fuchs, C. S. Aspirin use and survival after diagnosis of colorectal cancer. J.A.M.A. 302, 649-658 (2009
21. Viau, M., & Zouali, M. B-lymphocytes, innate immunity, and autoimmunity. Clin. Immunol. 114, 17-26 (2005
22. Hu, L., Dixit, V. D., de Mello-Coelho, V., & Taub, D. D. Age-Associated alterations in CXCL1 chemokine expression by murine B cells. BMC Immunol. 5, 15 (2004
23. Balkwill, F., Charles, K. A., & Mantovani, A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7, 211-217 (2005
24. de Visser, K. E., Korets, L. V., & Coussens, L. M. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7, 411-423 (2005
25. DeNardo, D. G., et al. CD4+ T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16, 91-102 (2009
26. Wight, T. N., Kang, I., & Merrilees, M. J. Versican and the control of inflammation. Matrix Biology 35, 152-161 (2014
27. Potente, M., Gerhardt, H., & Carmeliet, P. Basic and therapeutic aspects of angiogenesis. Cell 146, 873-887 (2011
28. Weis, S. M., & Cheresh, D. A. Tumor angiogenesis: molecular pathways and therapeutic targets. Nature Medicine 17 (11), 1359-1370 (2011
29. McEarchern, J. A., et al. Invasion and metastasis of a mammary tumor involves TGF-beta signaling. Int. J. Cancer 91, 76-82 (2001
30. Ali, K., et al. Inactivation of PI(3)K p110d breaks regulatory T-cell-mediated immune tolerance to cancer. Nature 510, 407-411 (2014
31. Zelenay, S., et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell 162, 1257-1270 (2015
32. Verheul, H. M., Panigrahy, D., Yuan, J., & D'Amato, R. J. Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits. British Journal of Cancer 79(1), 114-118 (1999
33. Chiu, C., McEntee, M. F., & Whelan, J. Sulindac causes rapid regression of preexisting tumors in Min/+ mice, independent of prostaglandin biosynthesis. Cancer Res. 57, 4267-4273 (1997
34. Zitvogel, L., Galluzzi, L., Smyth, M. J., & Kroemer, G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 39, 74-88 (2013
35. Vincent, J., et al. 5-Fluorouracil selectively kills tumor-Associated myeloid-derived suppressor cells resulting in enhanced T celldependent antitumor immunity. Cancer Res. 70, 3052-3061 (2010
36. Thomas-Schoemann, A., et al. Arsenic trioxide exerts antitumor activity through regulatory T cell depletion mediated by oxidative stress in a murine model of colon cancer. J. Immunol. 189, 5171-5177 (2012
37. Suzuki, E., Sun, J., Kapoor, V., Jassar, A. S., & Albelda, S. M. Gemcitabine has significant immunomodulatory activity in murine tumor models independent of its cytotoxic effects. Cancer Biol. Ther. 6, 880-885 (2007
38. Michaud, M., et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 334, 1573-1577 (2011
39. Menger, L., et al. Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci. Transl. Med. 4, 43ra99 (2012
40. Westervelt, P., et al. Adaptive immunity cooperates with liposomal all-Trans-retinoic acid (ATRA) to facilitate long-Termmolecular remissions in mice with acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA 99, 9468-9473 (2002
41. Balachandran, V. P., et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat. Med. 17, 1094-1100 (2011
42. Haanen, C. Sulindac and its derivatives: a novel class of anticancer agents. Curr. Opin. Investig. Drugs 2, 677-683 (2001
43. Sevko, A., et al. Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model. J. Immunol. 190, 2464-2471 (2013
44. Mattarollo, S. R., et al. Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res. 71, 4809-4820 (2011
45. Yang, Y., et al. Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood 120, 4533-4543 (2012
46. Knight, D. A., et al. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J. Clin. Invest. 123, 1371-1381 (2013
47. Gallina, G., et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J. Clin. Invest. 116, 2777-2790 (2006